Adam B. Shapiro

Adam B. Shapiro

Auto-generated profile, based on publicly available information

Adam B. Shapiro

Entasis Therapeutics, Gatehouse Park BioHub, Waltham, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1997 in European Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
ASAdam B. Shapiro
Adam B. Shapiro
VLVictor Ling
Victor Ling
In this paper, we show that P‐glycoprotein contains two distinct sites for drug binding and transport, and that, unexpectedly, these sites interact in a positively cooperative manner. The kinetics of transport of rhodamine 123 and Hoechst 33342 in isolated P‐glycoprotein‐rich plasma membrane vesicles from Chinese hamster ovary CHRB30 cells were followed by continuous fluorescence monitoring. Each substrate stimulated P‐glycoprotein‐mediated transport of the other. Colchicine and quercetin stimulated rhodamine 123 transport and inhibited Hoechst 33342 transport. In contrast, anthracyclines such as daunorubicin and doxorubicin stimulated Hoechst 33342 transport and inhibited rhodamine 123 transport. Vinblastine, actinomycin D, and etoposide inhibited transport of both dyes. The results are consistent with a functional model of P‐glycoprotein containing at least two positively cooperative sites (H site and R site) for drug binding and transport. This model is consistent with earlier observations of competitive and non‐competitive effects of P‐glycoprotein substrates and chemosensitizers. Such a two‐site model may be fundamental to multidrug transport by P‐glycoprotein, and it may be a feature common to other ATP‐dependent transporters belonging to the ATP‐binding cassette superfamily.

1 February 2001 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
FLFred C. Lam
Fred C. Lam
RLRonghua Liu
Ronghua Liu
PLPeihua Lu
Peihua Lu
ASAdam B. Shapiro
Adam B. Shapiro
JRJack‐Michel Renoir
Jack‐Michel Renoir
PRPeter B. Reiner
Peter B. Reiner

30 June 2017 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
TDThomas F. Durand-Réville
Thomas F. Durand-Réville
SGSatenig Guler
Satenig Guler
JCJanelle Comita-Prevoir
Janelle Comita-Prevoir
BCBrendan Chen
Brendan Chen
NBNeil Bifulco
Neil Bifulco
AMAlita A. Miller
Alita A. Miller

1 February 1999 in European Journal of Biochemistry
Verified
Journal Article
Closed access
ASAdam B. Shapiro
Adam B. Shapiro
KFKelly Fox
Kelly Fox
PLPing Lam
Ping Lam
VLVictor Ling
Victor Ling

1 March 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
WPWilliam F. Penwell
William F. Penwell
ASAdam B. Shapiro
Adam B. Shapiro
RGRobert A. Giacobbe
Robert A. Giacobbe
RGRong-Fang Gu
Rong-Fang Gu
NGNing Gao
Ning Gao
AMAlita A. Miller
Alita A. Miller
Sulbactam is a class A β-lactamase inhibitor with intrinsic whole-cell activity against certain bacterial species, including Acinetobacter baumannii . The clinical use of sulbactam for A. baumannii infections is of interest due to increasing multidrug resistance in this pathogen. However, the molecular drivers of its antibacterial activity and resistance determinants have yet to be precisely defined. Here we show that the antibacterial activities of sulbactam vary widely across contemporary A. baumannii clinical isolates and are mediated through inhibition of the penicillin-binding proteins (PBPs) PBP1 and PBP3, with very low frequency of resistance; the rare pbp3 mutants with high levels of resistance to sulbactam are attenuated in fitness. These results support further investigation of the potential clinical utility of sulbactam.

1 February 1997 in Biochemical Pharmacology
Verified
Journal Article
Closed access
ASAdam B. Shapiro
Adam B. Shapiro
VLVictor Ling
Victor Ling